Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipotecan Plus Radiotherapy in Locally Advanced HCC
NCT01425996Phase 2Terminated
- Sponsor
- Taiwan Liposome Company
- Start
- Oct 2011
- Primary completion
- Oct 2014
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lipotecan in hepatocellular carcinoma (HCC), sponsored by Taiwan Liposome Company. Primary endpoints: Maximum Tolerated Dose at week 12, Portal Vein Tumor Thrombosis Response Rate at week 7 and 2 more. Started Oct 2011; status: terminated.
02
Drugs
lipotecan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01425996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01425996.